ZEUS Scientific
Diagnostic innovation. Worldwide application.

April 22nd, 2020

ZEUS SCIENTIFIC ANNOUNCES NEW RAPID SARs-CoV-2 ANTIBODY TEST

ZEUS Scientific announces today the submission for an Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for its rapid, *in vitro* diagnostic test for the qualitative detection of IgG and/or IgM antibodies to the SARS-CoV-2 (novel 2019 Coronavirus).

ZEUS's lateral flow test uses patient serum, plasma or whole blood and provides results in 15 minutes. Assay performance has been confirmed by testing sample cohorts from healthy donors, confirmed positive COVID-19 patients and cross-reactive samples acquired from heavily afflicted regions in both China and the United States. The request for EUA is under review by the FDA and if received ZEUS expects to have the test available to ship to customers in early May 2020.

Rapid detection of cases and contacts, appropriate clinical management, infection control, and community mitigation efforts are critical to respond effectively to the COVID-19 pandemic. Results from the ZEUS test will help address the urgent health concerns surrounding the public health threat posed by COVID-19. Identifying individuals with specific antibodies to the SARS-CoV-2 virus provides valuable diagnostic information relating to previous exposure to the SARS-CoV-2 virus.

ZEUS Scientific is a trusted partner with over 40 years of *in vitro* diagnostic experience providing high quality diagnostic solutions. Our New Jersey

ZEUS Scientific, Inc.
P.O. Box 38, Raritan, New Jersey 08869
p.908 526 3744 800 286 2111 f.908 526 2058 www.zeusscientific.com

ZEUS Scientific
Diagnostic innovation. Worldwide application.

based, FDA-inspected manufacturing facility is certified and audited to ISO 13485 (2016), FDA Quality System Regulations (1996: 21 CFR § 820) and IVD 98/79/EEC. In these difficult times you can count on ZEUS to apply our expertise and assist in the fight against COVID-19.

In addition to this rapid *in vitro* diagnostic test, ZEUS is also pleased to announce development of a corresponding ELISA test system, also for detection of antibodies to SARS-CoV-2. Further updates in conjunction with this higher throughput, automatable option will be provided in the near future.

For more information please visit our website ZeusCovid.com or email sales@zeusscientific.com to ensure early access to the rapid test system when issuance of an EUA has been received and the product is released for sale.

ZEUS Scientific, Inc.
P.O. Box 38, Raritan, New Jersey 08869
p.908 526 3744 800 286 2111 f.908 526 2058 www.zeusscientific.com